Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > ACADEMIA
ACADEMIA
- A New Industry Could Be Created in the Field of Pre-Symptomatic Medical Intervention: Kyoto Univ. Prof. Kawakami
January 16, 2012
- Specialists Debate Pro, Cons of Early Pharm. Intervention in Dementia
January 16, 2012
- MD Studies Could Increase Development Success Rate to 30%: Prof. Sugiyama
December 20, 2011
- Kyushu University Professor Egashira Says Suppression of Vascular Inflammation Can Be Target for Development
November 30, 2011
- JDA Requests Additional Indication of Pustular Psoriasis for Humira
November 22, 2011
- JSMO Issues 33 Development Requests for Unapproved Drugs, Indications
November 22, 2011
- JUA Negative about OTC Switching of Propiverine Hydrochloride
November 17, 2011
- PSJ Preparing for Exchange of Views with JAMS on Switch-OTC Drug Candidates
November 15, 2011
- Teriparatide “Strongly Recommended” for Non-vertebral Fracture: JOS Draft GLs
November 7, 2011
- “No Major Ethnic Differences” in Pharmacokinetics of 3 Drugs Reported
November 1, 2011
- JSGM Calls for Elimination of GE Drug Refusal Option in Prescriptions
October 28, 2011
- JSGM Calls For Elimination of GE Drug Refusal Option in Prescriptions
October 27, 2011
- Kyowa Kirin’s KW-0761 Shows Promise for ATL: Prof. Tsukasaki of Nagasaki Univ.
October 20, 2011
- “No Major Differences” Between 4 AD Treatments; More Evidence Needed: Prof. Hanyu
October 20, 2011
- Positive Results for Avastin in Japanese PII Trial in Recurrent GBM: JNS
October 13, 2011
- Nexium Significantly Reduces Incidence of Acid Reflux Compared to Omepral: Study Report
October 10, 2011
- Prof. Uchiyama Stresses Need for Caution with Prazaxa Even at Low Dose
October 10, 2011
- JGS Opposes OTC Switch for 8 Ethical Drugs on Ground of Patients’ High Ages
October 7, 2011
- HRT is Cost Efficient Treatment: JSMWH
October 6, 2011
- Humira Top Choice Among Biopharmaceuticals for Psoriasis Treatment: Prof. Nakagawa
October 6, 2011
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…